Munich Reinsurance Co Stock Corp in Munich Has $8.70 Million Holdings in Cencora, Inc. $COR

Key Points

• Munich Reinsurance Co Stock Corp in Munich reduced its stake in Cencora by 57.9% in Q4, selling 35,127 shares and leaving 25,578 shares valued at about $8.70 million.
• Cencora reported Q4 EPS of $4.08, slightly beating estimates, while revenue of $85.93 billion rose 5.5% year‑over‑year but narrowly missed consensus.
• 97.52% of Cencora is owned by institutional investors and hedge funds; analysts rate the stock a "Moderate Buy" with an average price target of $398.17, and the company pays a quarterly dividend of $0.60 (0.8% yield).

Munich Reinsurance Co Stock Corp in Munich reduced its position in Cencora, Inc. (NYSE:COR - Free Report) by 57.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,578 shares of the company's stock after selling 35,127 shares during the period. Munich Reinsurance Co Stock Corp in Munich's holdings in Cencora were worth $8,698,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Cencora by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company's stock worth $7,311,810,000 after purchasing an additional 916,506 shares during the last quarter. State Street Corp increased its holdings in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company's stock valued at $2,872,249,000 after acquiring an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Cencora by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company's stock valued at $1,461,965,000 after acquiring an additional 821,098 shares during the last quarter. Boston Partners increased its holdings in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company's stock valued at $1,409,152,000 after acquiring an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company's stock valued at $1,241,094,000 after acquiring an additional 115,278 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR stock opened at $307.60 on Friday. The stock has a 50 day moving average of $337.33 and a two-hundred day moving average of $343.02. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12 month low of $271.00 and a 12 month high of $377.54. The company has a market capitalization of $59.84 billion, a P/E ratio of 36.97, a P/E/G ratio of 1.45 and a beta of 0.72.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts' consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter last year, the company earned $3.73 EPS. The company's quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities analysts expect that Cencora, Inc. will post 17.57 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio (DPR) is currently 28.85%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on COR shares. Leerink Partners reissued an "outperform" rating on shares of Cencora in a report on Tuesday, March 17th. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the company an "overweight" rating in a report on Friday, February 13th. Wells Fargo & Company increased their price objective on Cencora from $405.00 to $429.00 and gave the company an "overweight" rating in a report on Tuesday, February 10th. Bank of America lowered their price objective on Cencora from $380.00 to $360.00 and set a "neutral" rating on the stock in a report on Monday, January 5th. Finally, Jefferies Financial Group raised Cencora from an "underperform" rating to a "buy" rating in a report on Thursday, January 22nd. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $398.17.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.